Abstract
Retinal neovascularization is central to the pathogenesis of proliferative diabetic retinopathy, the leading cause of blindness among the middle-aged population. Angiostatin, a proteolytic fragment of plasminogen is one of the most promising inhibitors of angiogenesis currently in clinical trials. Here we show that recombinant angiostatin can inhibit retinal neovascularization in a mouse model of proliferative retinopathy. Because proliferative diabetic retinopathy is a recurrent disease, effective therapy will need to be sustained. Recombinant adeno-associated viruses permit long-term expression of transfected genes; however, they can only accommodate a small insert sequence. Thus, we engineered and tested a shortened recombinant angiostatin derivative containing a signal sequence to permit secretion. Recombinant protein was purified from the medium of transfected HEK293 cells and injected subcutaneously into treated animals. The retinal vasculature was analyzed in retinal flat mounts and using immunohistochemically stained sections. Both methods demonstrate that this short, secreted form of angiostatin is effective in reducing the development of blood vessels in a nontumor environment and has therapeutic potential for neovasc...Continue Reading
References
Oct 21, 1994·Cell·M S O'ReillyJ Folkman
May 1, 1994·Survey of Ophthalmology·L M JampolM H Goldbaum
Apr 16, 1998·Diabetes Care·L P AielloR Klein
Aug 26, 1999·The New England Journal of Medicine·F L FerrisL M Aiello
Citations
Jun 19, 2004·Rheumatology International·Ko KatoTakashi Shimada
Oct 25, 2003·Progress in Retinal and Eye Research·Arup Das, Paul G McGuire
Jul 11, 2003·Progress in Retinal and Eye Research·Ray F Gariano
Nov 9, 2001·Drug Discovery Today·Henrik S. RasmussenLisa Wei
Jun 21, 2013·DNA and Cell Biology·Kenneth I Berns
Sep 16, 2003·Retina·John R HeckenlivelyBo Chang
Jan 8, 2005·Ophthalmic Research·Chi-Chun LaiYeou-Ping Tsao
Jun 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Brian J RaislerWilliam W Hauswirth
Jan 17, 2007·Expert Opinion on Biological Therapy·Mariacarmela AlloccaAlberto Auricchio
Jan 26, 2016·Pharmacogenomics·Aniruddha AgarwalQuan Dong Nguyen
Nov 1, 2006·Progress in Retinal and Eye Research·Sarah X Zhang, Jian-xing Ma
Jul 22, 2008·Brain Research·Norbert GyongyosiGyorgy Bagdy
Mar 29, 2005·Diabetes·Corinna LebherzJean Bennett
Apr 20, 2004·FEBS Letters·Jing SimaJian-xing Ma
Jan 6, 2006·Journal of the American Society of Nephrology : JASN·Sarah X ZhangJian-Xing Ma
Aug 29, 2006·Oncogene·H HelmboldW Bohn
Apr 20, 2005·Oncogene·Maria A Ciemerych, Peter Sicinski
Apr 20, 2005·Oncogene·Xin-Hai Pei, Yue Xiong
Feb 3, 2005·Oncogene·Maya Ameyar-ZazouaJonathan B Weitzman
Sep 6, 2019·International Journal of Molecular Sciences·Jessica K W TsangAmy C Y Lo
Nov 7, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tetyana LevchenkoLars Holmgren
Feb 27, 2016·Current Opinion in Ophthalmology·Robert B Garoon, J Timothy Stout